Clinical measures in transthyretin familial amyloid polyneuropathy

被引：53
|
作者：
Coelho, Teresa [1 ]
Vinik, Aaron [2 ]
Vinik, Etta J. [2 ]
Tripp, Tara [3 ]
Packman, Jeff [4 ]
Grogan, Donna R. [4 ]
机构：
[1] Hosp Santo Antonio, Ctr Hosp Porto, P-4099001 Oporto, Portugal
[2] Eastern Virginia Med Sch, Strelitz Diabet Ctr, Norfolk, VA 23501 USA
[3] DM Stat Inc, Malden, MA USA
[4] FoldRx Pharmaceut Inc, Cambridge, MA USA
来源：
MUSCLE & NERVE | 2017年 / 55卷 / 03期
关键词：
amyloidosis; modified body mass index; nerve fiber function; Neuropathy Impairment Score; Norfolk Quality of Life; ROCHESTER DIABETIC-NEUROPATHY; RETINOL-BINDING-PROTEIN; LIVER-TRANSPLANTATION; FOLLOW-UP; PERIPHERAL NEUROPATHY; END-POINTS; TAFAMIDIS; SURVIVAL; TRIAL; DYSFUNCTION;
D O I：
10.1002/mus.25257
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
IntroductionThis observational, cross-sectional, single-center study aimed to identify instruments capable of measuring disease progression in transthyretin familial amyloid polyneuropathy (TTR-FAP). MethodsThe relationship between disease stage and Neuropathy Impairment Score-Lower Limbs (NIS-LL) and Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QOL-DN) total score was assessed in 61 (stages 1-3) patients with TTR-FAP (V30M variant) and 16 healthy controls. Composite measures of large- and small-nerve fiber function, and modified body mass index (mBMI) were also assessed. ResultsOrdinal-based NIS-LL and Norfolk QOL-DN scores discriminated between disease stages (P<0.0001 for NIS-LL and Norfolk QOL-DN). Longer disease duration correlated with worse NIS-LL and Norfolk QOL-DN. Karnofsky performance score declined progressively by disease stage. Composite measures of nerve fiber function differentiated stage 1 from stage 2 disease. The mBMI declined with advancing disease. ConclusionsNIS-LL, Norfolk QOL-DN score, composite endpoints of nerve fiber function, and mBMI are valid, reliable measures of TTR-FAP severity. Muscle Nerve55: 323-332, 2017
引用
收藏
页码：323 / 332
页数：10
相关论文
共 50 条
  • [21] Brazilian consensus for diagnosis, management and treatment of transthyretin familial amyloid polyneuropathy
    Pinto, Marcus Vinicius
    Barreira, Amilton Antunes
    Bulle, Acary Souza
    Gomes de Freitas, Marcos Raimundo
    Franca Jr, Rcondes Cavalcante
    Aquino Gondim, Francisco de Assis
    Marrone, Carlo Domenico
    Marques Jr, Wilson
    Nascimento, Osvaldo J. M.
    Rotta, Francisco Tellechea
    Pupe, Camila
    Waddington-Cruz, Marcia
    ARQUIVOS DE NEURO-PSIQUIATRIA, 2018, 76 (09) : 609 - 621
  • [22] Impact of Non-Cardiac Clinicopathologic Characteristics on Survival in Transthyretin Amyloid Polyneuropathy
    Gonzalez-Duarte, Alejandra
    Conceicao, Isabel
    Amass, Leslie
    Botteman, Marc F.
    Carter, John A.
    Stewart, Michelle
    NEUROLOGY AND THERAPY, 2020, 9 (01) : 135 - 149
  • [23] Loss of functional albumin triggers acceleration of transthyretin amyloid fibril formation in familial amyloidotic polyneuropathy
    Kugimiya, Tomoe
    Jono, Hirofumi
    Saito, Shiori
    Maruyama, Toru
    Kadowaki, Daisuke
    Misumi, Yohei
    Hoshii, Yoshinobu
    Tasaki, Masayoshi
    Su, Yu
    Ueda, Mitsuharu
    Obayashi, Konen
    Shono, Makoto
    Otagiri, Masaki
    Ando, Yukio
    LABORATORY INVESTIGATION, 2011, 91 (08) : 1219 - 1228
  • [24] Recommendations regarding diagnosis and treatment of transthyretin familial amyloid polyneuropathy
    Garcia-Pavia, Pablo
    Munoz-Beamud, Francisco
    Casasnovas, Carlos
    MEDICINA CLINICA, 2015, 145 (05): : 211 - 217
  • [25] Repurposing Diflunisal for Familial Amyloid Polyneuropathy A Randomized Clinical Trial
    Berk, John L.
    Suhr, Ole B.
    Obici, Laura
    Sekijima, Yoshiki
    Zeldenrust, Steven R.
    Yamashita, Taro
    Heneghan, Michael A.
    Gorevic, Peter D.
    Litchy, William J.
    Wiesman, Janice F.
    Nordh, Erik
    Corato, Manuel
    Lozza, Alessandro
    Cortese, Andrea
    Robinson-Papp, Jessica
    Colton, Theodore
    Rybin, Denis V.
    Bisbee, Alice B.
    Ando, Yukio
    Ikeda, Shu-ichi
    Seldin, David C.
    Merlini, Giampaolo
    Skinner, Martha
    Kelly, Jeffery W.
    Dyck, Peter J.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (24): : 2658 - 2667
  • [26] Current and Future Treatment Approaches in Transthyretin Familial Amyloid Polyneuropathy
    Philippe Kerschen
    Violaine Planté-Bordeneuve
    Current Treatment Options in Neurology, 2016, 18
  • [27] First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy
    Adams, David
    Suhr, Ole B.
    Hund, Ernst
    Obici, Laura
    Tournev, Ivailo
    Campistol, Josep M.
    Slama, Michel S.
    Hazenberg, Bouke P.
    Coelho, Teresa
    CURRENT OPINION IN NEUROLOGY, 2016, 29 : S14 - S26
  • [28] Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy
    Coelho, Teresa
    Maia, Luis F.
    da Silva, Ana Martins
    Cruz, Marcia W.
    Plante-Bordeneuve, Violaine
    Suhr, Ole B.
    Conceicao, Isabel
    Schmidt, Hartmut H. -J.
    Trigo, Pedro
    Kelly, Jeffery W.
    Labaudiniere, Richard
    Chan, Jason
    Packman, Jeff
    Grogan, Donna R.
    JOURNAL OF NEUROLOGY, 2013, 260 (11) : 2802 - 2814
  • [29] Ocular manifestations of transthyretin-related familial amyloid polyneuropathy
    Antoine Rousseau
    Emmanuel Barreau
    Julia Meney
    Zoia Mincheva
    Cécile Cauquil
    Marie Théaudin
    Marc Labetoulle
    David Adams
    Orphanet Journal of Rare Diseases, 10 (Suppl 1)
  • [30] Familial Amyloid Polyneuropathy
    Cakar, Arman
    Durmus-Tekce, Hacer
    Parman, Yesim
    NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2019, 56 (02): : 150 - 156
12345